|
|
|
New Study Underscores Biopharma Contribution
An economic study issued March 5
underscores the contribution to Connecticut’s economy of its
pharmaceutical research and biotechnology companies. The study showed
that the presence of biopharmaceutical companies, and the jobs they
support, make substantial contributions to state economies.
"Biotech, medical devices, and pharma are the engines driving the
knowledge-based 21st-century Connecticut economy," said Paul
Pescatello, president and CEO of CURE. "These industries pay high
salaries and wages, attract investment capital and an educated
workforce to the state, and promote fruitful interaction with our
outstanding research universities."
The study was conducted by Archstone Consulting and Dr. Lawton R.
Burns, Director, The Wharton Center for Health Management and Economics
at The Wharton School, University of Pennsylvania, and was commissioned
by the Pharmaceutical Research and Manufacturers of America (PhRMA).
Click
here for press release. Click here for executive summary of the
report.
Separately,
Pescatello testified March 9 in Hartford against
several bills that would complicate physicians' practice of medicine
and add regulation to the interactions between doctors and
biopharmaceutical
companies. He
said the law would "just add to the
regulatory burdens and costs of doing business" because drug company
representatives would have to spend time, resources, and energy
figuring
out "what is allowed and what isn't each time a drug company
representative tries to interact with a doctor."
Pescatello
stressed that the proposed legislation is duplicative of an array
of federal laws and regulations, as well as several professional
codes of
conduct, and that its burdens would be especially onerous for small
biotech
companies.
He added that approval of the bill would send the wrong message to an
industry the state is trying to cultivate.
Click
here for article from The Day.
|
|
|
